TMI vs. BPCR, USG, EGT, PU12, CYS, GV2O, TV2H, WINV, TAN, and AAM
Should you be buying Taylor Maritime Investments stock or one of its competitors? The main competitors of Taylor Maritime Investments include BioPharma Credit (BPCR), Ultimate Sports Group (USG), European Green Transition Plc O (EGT), Puma VCT 12 (PU12), Chrysalis VCT (CYS), Gresham House Renewable Energy VCT 2 (GV2O), Thames Ventures VCT 2 Healthcare Shs (TV2H), Worsley Investors (WINV), Tanfield Group (TAN), and Artemis VCT PLC Fund O Inc (AAM.L) (AAM). These companies are all part of the "asset management" industry.
Taylor Maritime Investments vs. Its Competitors
Taylor Maritime Investments (LON:TMI) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
In the previous week, Taylor Maritime Investments' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.
Taylor Maritime Investments has a net margin of 87.36% compared to BioPharma Credit's net margin of 80.20%. Taylor Maritime Investments' return on equity of 16.59% beat BioPharma Credit's return on equity.
Taylor Maritime Investments has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.
7.5% of Taylor Maritime Investments shares are held by institutional investors. Comparatively, 21.4% of BioPharma Credit shares are held by institutional investors. 2.8% of Taylor Maritime Investments shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BioPharma Credit has higher revenue and earnings than Taylor Maritime Investments. Taylor Maritime Investments is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
Taylor Maritime Investments pays an annual dividend of GBX 8 per share and has a dividend yield of 1,000.0%. BioPharma Credit pays an annual dividend of GBX 0.07 per share and has a dividend yield of 7.7%. Taylor Maritime Investments pays out -3,340.3% of its earnings in the form of a dividend. BioPharma Credit pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Taylor Maritime Investments is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
BioPharma Credit beats Taylor Maritime Investments on 7 of the 13 factors compared between the two stocks.
Get Taylor Maritime Investments News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMI and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taylor Maritime Investments Competitors List
Related Companies and Tools
This page (LON:TMI) was last updated on 9/14/2025 by MarketBeat.com Staff
Free TMI Stock Alerts